| Assay ID | Title | Year | Journal | Article |
|---|
| AID1334802 | Oral bioavailability in Sprague-Dawley rat at 3 mg/kg | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334774 | Inhibition of CYP3A4 (unknown origin) | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334786 | Displacement of [3H]-N-Methylscopolamine from human M3 receptor expressed in CHOK1 cells | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334764 | Positive allosteric modulation of human M4 receptor expressed in CHO cells co-expressing Gqui5 by calcium mobilization assay | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334760 | Positive allosteric modulation of rat M4 receptor expressed in CHO cells co-expressing Gqui5 by calcium mobilization assay | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334775 | Plasma clearance in Sprague-Dawley rat at 1 mg/kg, iv | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334766 | Intrinsic clearance in rat | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1366825 | Positive allosteric modulation of human M4 receptor expressed in CHO cells co-expressing Gqi5 assessed as increase in acetylcholine-induced calcium mobilization | 2017 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
| Challenges in the development of an M |
| AID1334779 | Ratio of unbound concentration in brain to plasma in Sprague-Dawley rat at 1 mg/kg, ip at 0.25 hrs | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1366829 | Brain to plasma partition coefficient, Kp of the compound in Sprague-Dawley rat at 0.1 to 0.2 mg/kg, iv measured after 0.25 hrs | 2017 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
| Challenges in the development of an M |
| AID1334780 | Reversal of amphetamine-induced hyperlocomotion in Sprague-Dawley rat at 10 mg/kg, po administered 30 mins after habituation in the chamber followed by amphetamine injection measured for 60 mins | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334770 | Unbound fraction in rat brain | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1453538 | Reversal of amphetamine-induced hyperlocomotion in Sprague-Dawley rat at 10 mg/kg, po pretreated 30 mins post habituation in the chamber followed by amphetamine injection after 30 mins measured after 60 mins | 2017 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
| Challenges in the development of an M |
| AID1334772 | Inhibition of CYP2C9 (unknown origin) | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334761 | Positive allosteric modulation of rat M4 receptor expressed in CHO cells co-expressing Gqui5 by calcium mobilization assay relative to acetylcholine | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334767 | Intrinsic clearance in human | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1588273 | Antipsychotic activity in Sprague-Dawley rat assessed as reversal of amphetamine-induced hyperlocomotion at 10 mg/kg, po pretreated 30 mins followed by addition of amphetamine and measured after 1 hr | 2019 | Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
| SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M |
| AID1366827 | Clearance in Sprague-Dawley rat plasma at 0.1 to 1 mg/kg, iv | 2017 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
| Challenges in the development of an M |
| AID1334799 | Inhibition of human adenosine transporter assessed as reduction in [3H]-adenosine uptake | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334785 | Displacement of [3H]-N-Methylscopolamine from human M2 receptor expressed in CHOK1 cells | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334768 | Unbound fraction in rat plasma | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334778 | Ratio of total drug level in Sprague-Dawley rat brain to plasma at 1 mg/kg, ip at 0.25 hrs | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1366826 | Positive allosteric modulation of human M4 receptor expressed in CHO cells co-expressing Gqi5 assessed as increase in acetylcholine-induced calcium mobilization relative to acetylcholine | 2017 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
| Challenges in the development of an M |
| AID1334765 | Positive allosteric modulation of human M4 receptor expressed in CHO cells co-expressing Gqui5 by calcium mobilization assay relative to acetylcholine | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334790 | Binding affinity to rat M3 receptor by radio-ligand binding assay | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334781 | Reversal of amphetamine-induced hyperlocomotion in Sprague-Dawley rat at 30 mg/kg, po administered 30 mins after habituation in the chamber followed by amphetamine injection measured for 60 mins | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334782 | Ratio of total drug level in mouse brain to plasma | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334783 | Reversal of amphetamine-induced hyperlocomotion in Sprague-Dawley rat at 3 mg/kg, po administered 30 mins after habituation in the chamber followed by amphetamine injection measured for 60 mins | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334776 | Half life in Sprague-Dawley rat at 1 mg/kg, iv | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334784 | Displacement of [3H]-N-Methylscopolamine from human M1 receptor expressed in CHOK1 cells | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1366831 | Aqueous solubility of the compound at pH 7.4 | 2017 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
| Challenges in the development of an M |
| AID1334791 | Binding affinity to rat M5 receptor by radio-ligand binding assay | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334771 | Inhibition of CYP1A2 (unknown origin) | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334789 | Binding affinity to rat M2 receptor by radio-ligand binding assay | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334777 | Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334788 | Binding affinity to rat M1 receptor by radio-ligand binding assay | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1366830 | Ratio of unbound brain to plasma concentration in Sprague-Dawley rat at 0.1 to 0.2 mg/kg, iv measured after 0.25 hrs | 2017 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
| Challenges in the development of an M |
| AID1334787 | Binding affinity to human M5 receptor by radio-ligand binding assay | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1334773 | Inhibition of CYP2D6 (unknown origin) | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1366204 | Positive allosteric modulation of rat M4 receptor expressed in CHO cells co-expressing Gqi5 assessed as increase in acetylcholine-induced calcium mobilization | 2017 | Bioorganic & medicinal chemistry letters, 11-15, Volume: 27, Issue:22
| Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M |
| AID1334769 | Unbound fraction in human plasma | 2017 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2
| Challenges in the development of an M |
| AID1366828 | Elimination half life in Sprague-Dawley rat at 0.1 to 1 mg/kg, iv | 2017 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 27, Issue:23
| Challenges in the development of an M |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |